Tevimbra

Monotherapy for patients w/ locally advanced or metastatic NSCLC after prior chemotherapy & for patients w/ unresectable, recurrent, locally advanced or metastatic oesophageal squamous cell carcinoma after prior chemotherapy. In combination w/ pemetrexed & platinum-containing chemotherapy for the 1st-line treatment of adults w/ non-squamous NSCLC whose tumours have PD-L1 expression on ≥50% of tumour cells w/ no EGFR or ALK +ve mutations & who have locally advanced NSCLC & are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC. In combination w/ carboplatin & either paclitaxel or nab-paclitaxel is indicated for 1st-line treatment of adults w/ squamous NSCLC who have locally advanced NSCLC & are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC.

IV infusion Monotherapy: 200 mg once every 3 wk. Combination therapy: 200 mg once every 3 wk in combination w/ chemotherapy.

Hypersensitivity.

Cancer Immunotherapy

L01FF09 - tislelizumab ; Belongs to the class of PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors. Used in the treatment of cancer.

POM